|
1
|
Spiro S: Lung cancer: principles and
practice. Br J Cancer. 85:16092001. View Article : Google Scholar
|
|
2
|
Bosset JF, Calais G, Mineur L, et al:
Enhanced tumorocidal effect of chemotherapy with preoperative
radiotherapy for rectal cancer: preliminary results-EORTC 22921. J
Clin Oncol. 23:5620–5627. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rougier P, Bugat R, Douillard JY, et al:
Phase II study of irinotecan in the treatment of advanced
colorectal cancer in chemotherapy-naive patients and patients
pretreated with fluorouracil-based chemotherapy. J Clin Oncol.
15:251–260. 1997.PubMed/NCBI
|
|
4
|
Jiang WQ, Fu FF, Li YX, et al: Molecular
biomarkers of colorectal cancer: prognostic and predictive tools
for clinical practice. J Zhejiang Univ Sci B. 13:663–675. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar
|
|
6
|
Lippman SM: The dilemma and promise of
cancer chemoprevention. Nat Clin Pract Oncol. 3:5232006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Longley DB, Allen WL and Johnston PG: Drug
resistance, predictive markers and pharmacogenomics in colorectal
cancer. Biochim Biophys Acta. 1766:184–196. 2006.PubMed/NCBI
|
|
8
|
Gordaliza M: Natural products as leads to
anticancer drugs. Clin Transl Oncol. 9:767–776. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jia L: Cancer complementary and
alternative medicine research at the US National Cancer Institute.
Chin J Integr Med. 18:325–332. 2012. View Article : Google Scholar
|
|
10
|
Carmady B and Smith CA: Use of Chinese
medicine by cancer patients: a review of surveys. Chin Med. 6:1–8.
2011. View Article : Google Scholar
|
|
11
|
Tan KY, Liu CB, Chen AH, et al: The role
of traditional Chinese medicine in colorectal cancer treatment.
Tech Coloproctol. 12:1–6. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chinese Pharmacopoeia Commission.
Pharmacopoeia of the People’s Republic of China. 1. Chinese Medical
Science and Technology Press; pp. 109–110. 2010
|
|
13
|
Kim KW, Jin UH, Kim DI, et al:
Antiproliferative effect of Scutellaria barbata D. Don. on
cultured human uterine leiomyoma cells by down-regulation of the
expression of Bcl-2 protein. Phytother Res. 22:583–590. 2008.
|
|
14
|
Dai ZJ, Wang XJ, Xue Q, et al: Effects of
Scutellaria Barbata drug-containing serum on apoptosis and
mitochondrial transmembrane potential of hepatoma H22 cells. Zhong
Xi Yi Jie He Xue Bao. 6:821–826. 2008.(In Chinese).
|
|
15
|
Wei PY, Pu HQ, Wei X, Li CG and Nong S:
Apoptosis-inducing effect of Scutellaria barbata extract on
human lung cancer SPC-A-1 cells and the expression of apoptosis
associated genes. Zhong Yao Cai. 30:1270–1273. 2007.(In
Chinese).
|
|
16
|
Fong S, Shoemaker M, Cadaoas J, et al:
Molecular mechanisms underlying selective cytotoxic activity of
BZL101, an extract of Scutellaria barbata, towards breast
cancer cells. Cancer Biol Ther. 7:577–586. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wei L, Lin J, Wu G, et al: Scutellaria
barbata D. Don induces G1/S arrest via modulation of p53 and
Akt pathways in human colon carcinoma cells. Oncol Rep.
29:1623–1628. 2013.
|
|
18
|
Wei L, Lin J, Xu W, et al: Scutellaria
barbata D. Don inhibits tumor angiogenesis via suppression of
Hedgehog pathway in a mouse model of colorectal cancer. Int J Mol
Sci. 13:9419–9430. 2012. View Article : Google Scholar
|
|
19
|
Adams J and Cory S: The Bcl-2 apoptotic
switch in cancer development and therapy. Oncogene. 26:1324–1337.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Adams JM and Cory S: Bcl-2-regulated
apoptosis: mechanism and therapeutic potential. Curr Opin Immunol.
19:488–496. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Serrano M, Hannon GJ and Beach D: A new
regulatory motif in cell-cycle control causing specific inhibition
of cyclin D/CDK4. Nature. 366:704–707. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Resnitzky D, Gossen M, Bujard H and Reed
S: Acceleration of the G1/S phase transition by expression of
cyclins D1 and E with an inducible system. Mol Cell Biol.
14:1669–1679. 1994.PubMed/NCBI
|
|
23
|
Chung DC, Brown SB, Graeme-Cook F, et al:
Overexpression of cyclin D1 occurs frequently in human pancreatic
endocrine tumors. J Clin Endocrinol Metab. 85:4373–4378.
2000.PubMed/NCBI
|
|
24
|
Kim H, Ham EK, Kim YI, et al:
Overexpression of cyclin D1 and cdk4 in tumorigenesis of sporadic
hepatoblastomas. Cancer Lett. 131:177–183. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Keum J, Kong G, Yang S, et al: Cyclin D1
overexpression is an indicator of poor prognosis in resectable
non-small cell lung cancer. Br J Cancer. 81:127–132. 1999.
View Article : Google Scholar : PubMed/NCBI
|
